Branched-chain amino acids (BCAA), including leucine, isoleucine and valine, play a key role in human metabolism. As regulators of protein synthesis, nutrient signaling and metabolic homeostasis, they are widely used in sports nutrition and clinical practice because of their anabolic properties and ability to enhance muscle protein synthesis. Paradoxically, however, elevated circulating BCAA concentrations are consistently associated with insulin resistance (IR), type 2 diabetes, overfeeding and obesity in humans, while preclinical studies suggest that chronic BCAA excess can contribute to IR, particularly in the context of overfeeding. Conversely, metabolic benefits observed following dietary BCAA restriction or pharmacological enhancement of BCAA catabolism have raised interest in this pathway as a potential therapeutic target. Yet, tissue-specific genetic models demonstrate that lowering circulating BCAA concentrations alone is not sufficient to improve insulin sensitivity, while human studies provide limited evidence for consistent effects of BCAA manipulation on insulin sensitivity or appetite regulation. Collectively, these findings suggest that BCAA and their downstream metabolites should not be considered merely as circulating biomarkers or metabolic substrates, but as components of a tissue-specific metabolic network coordinating nutrient sensing, mitochondrial metabolism and inter-organ communication.